目的 探討寧泌泰膠囊聯(lián)合萘哌地爾治療慢性非細(xì)菌性前列腺炎的療效觀察。方法 選取2017年5月-2019年5月在河南大學(xué)淮河醫(yī)院泌尿科住院治療的106例慢性非細(xì)菌性前列腺炎患者為研究對(duì)象，按照隨機(jī)數(shù)字表法分成對(duì)照組和治療組，每組各有53例。對(duì)照組患者口服萘哌地爾分散片，起始劑量為25 mg/次，1次/d，1周后未到理想療效，可增加到50 mg/次，1次/d，飯后服用。治療組在對(duì)照組基礎(chǔ)上口服寧泌泰膠囊，3~4粒/次，3次/d，飯后服用。兩組患者均連續(xù)治療7 d。觀察兩組的臨床療效，比較兩組臨床癥狀的消失時(shí)間；同時(shí)比較兩組最大尿流率、平均尿流率、前列腺液中炎性因子的變化情況。結(jié)果 治療后，治療組總有效率96.23%，顯著高于對(duì)照組的83.02%（P<0.05）。治療后，治療組患者尿頻消退時(shí)間、尿急消退時(shí)間、排尿困難消退時(shí)間均顯著短于對(duì)照組（P<0.05）。治療后，兩組患者最大尿流率、平均尿流率均較治療前顯著提高（P<0.05）；且治療后，治療組最大尿流率、平均尿流率顯著高于對(duì)照組（P<0.05）。治療后，兩組患者前列腺液中炎性因子白細(xì)胞介素-2（IL-2）、白細(xì)胞介素-6（IL-6）、白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子α（TNF-α）水平均較治療前顯著降低（P<0.05）；治療后，治療組前列腺液中炎性因子水平顯著對(duì)于對(duì)照組（P<0.05）。結(jié)論 寧泌泰膠囊聯(lián)合萘哌地爾治療慢性非細(xì)菌性前列腺炎具有較好的臨床療效，能有效改善前列腺局部炎癥反應(yīng)，減低局部炎性細(xì)胞因子水平，在臨床上具有一定的參考價(jià)值。

Objective To investigate the curative effect of Ningmitai Capsules combined with naftopidil in treatment of chronic nonbacterial prostatitis. Methods A total of 106 patients with chronic non-bacterial prostatitis who were hospitalized in the Department of Urology of Huaihe Hospital of Henan University from May 2017 to May 2019 were selected as the research subjects. According to the random number table method, they were divided into control group and treatment group, with 53 patients in each group. Patients in the control group were po administered with Naftopidil Dispersible Tablets after meals, and the initial dosage was 25 mg/time, once daily. If the effect was not satisfactory after 1 week, the dosage could be increased to 50 mg/time, once daily. Patients in the treatment group were po administered with Ningmitai Capsules after meals on the basis of the control group, 3-4 grains/time, three times daily. Patients in both groups were treated continuously for 7 d. The clinical efficacy of the two groups was observed, and the disappearance time of clinical symptoms was compared between the two groups. The maximum urinary flow rate, mean urinary flow rate and inflammatory factors in prostatic fluid were compared between the two groups. Results After treatment, the total effective rate of treatment group was 96.23%, which was significantly higher than that of control group (83.02%, P<0.05). After treatment, the subsidence time of frequency, urgency and dysuria in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the maximum and average urinary flow rate in two groups were significantly increased compared with before treatment (P<0.05); After treatment, the maximum and average urinary flow rate in treatment group were significantly higher than those in control group (P<0.05). After treatment, the levels of IL-2, IL-6, IL-1β, and TNF-α in prostatic fluid of two groups were significantly decreased compared with before treatment (P<0.05). After treatment, the level of inflammatory factors in prostatic fluid in treatment group was significantly higher than that in control group (P<0.05). Conclusion Ningmitai Capsules combined with naftopidil has a good clinical effect in treatment of chronic non-bacterial prostatitis, and can effectively improve the local inflammatory response of the prostate, reduce the level of local inflammatory cytokines, which has a certain reference value in clinical practice.

R983

河南省科技發(fā)展計(jì)劃項(xiàng)目（192102310109）